AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30360210 — intervention group
Group type: COMPARATOR
Intervention: Conventional orthodontic composite resin (Transbond XT)
Number of subjects: 60
Study 30360210 — intervention group
Group type: EXPERIMENTAL
Intervention: NP1 (1% YF3 nanoparticles)
Number of subjects: 60
Study 30360210 — intervention group
Group type: EXPERIMENTAL
Intervention: NP2 (2% YF3 nanoparticles)
Number of subjects: 60
Study 30360210 — intervention group
Group type: EXPERIMENTAL
Intervention: NP3 (3% YF3 nanoparticles)
Number of subjects: 60
Study 28592584 — intervention group
Group type: EXPERIMENTAL
Intervention: ACP video intervention
Number of subjects: 0
Study 28592584 — intervention group
Group type: COMPARATOR
Intervention: Control video (informational video about the hospital surgical programme)
Number of subjects: 0
Study 24661235 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.8 mL of 4% articaine with 1 : 100 000 epinephrine
Number of subjects: 234
Study 24661235 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.6 mL of 4% articaine with 1 : 100 000 epinephrine
Number of subjects: 234
Study 24661235 — intervention group
Group type: COMPARATOR
Intervention: 1.8 mL of 4% articaine with 1 : 100 000 epinephrine (initial IANB)
Number of subjects: 234
Study 22361894 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-Based Learning (PBL)
Number of subjects: 39
Study 22361894 — intervention group
Group type: COMPARATOR
Intervention: Traditional method with study skills instruction
Number of subjects: 39
Study 22361894 — intervention group
Group type: COMPARATOR
Intervention: Traditional method without study skills instruction
Number of subjects: 39
Study 22123795 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal care (LC) - 1 year of telephone-based chronic disease management with continued counseling and nicotine replacement therapy for an additional 48 weeks.
Number of subjects: 443
Study 22123795 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC) - 8 weeks of evidence-based treatment with 2 additional counseling calls.
Number of subjects: 443
Study 22123795 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal care (LC) - compared to UC, LC participants received more counseling calls (mean, 16.5 vs 5.8 calls; P < .001), longer total duration of counseling (283 vs 117 minutes; P < .001), and more nicotine replacement therapy (4.7 vs 2.4 boxes of patches; P < .001).
Number of subjects: 443
Study 22123795 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal care (LC) - adjusted odds ratio for prolonged abstinence at 18 months was 1.74 (95% CI, 1.08‐2.80).
Number of subjects: 443
Study 22123795 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal care (LC) - participants who did not quit reduced smoking more than UC participants (significant only at 12 months).
Number of subjects: 443
Study 19595103 — intervention group
Group type: EXPERIMENTAL
Intervention: Microendoscopic discectomy (MED)
Number of subjects: 186
Study 19595103 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous lumbar discectomy (PLD)
Number of subjects: 186
Study 17203621 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressants for treatment of Post Stroke Depression (PSD)
Number of subjects: 0
Study 12949684 — intervention group
Group type: EXPERIMENTAL
Intervention: Impaza (antibodies to endothelial NO synthase in ultralow doses)
Number of subjects: 0
Study 12949684 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 12949684 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil
Number of subjects: 0
Study 11004016 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine (30 g over 30 min)
Number of subjects: 18
Study 11004016 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone-releasing peptide-2 (1 microg/kg)
Number of subjects: 18
Study 11004016 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of L-arginine and growth hormone-releasing peptide-2
Number of subjects: 18
Study 11004016 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 18
Study 9315992 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 339
Study 9315992 — intervention group
Group type: COMPARATOR
Intervention: Risperidone
Number of subjects: 339
Study 8384435 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand-sutured ileoanal anastomosis (group 1)
Number of subjects: 40
Study 8384435 — intervention group
Group type: COMPARATOR
Intervention: Double-stapled ileoanal anastomosis (group 2)
Number of subjects: 40
Study 31678060 — intervention group
Group type: EXPERIMENTAL
Intervention: Photobiomodulation therapy (PBMT) with 940nm, 2.5W, 120s, 85.71J/cm2, 0.89W/cm2, three times per week for two weeks (G1)
Number of subjects: 60
Study 31678060 — intervention group
Group type: EXPERIMENTAL
Intervention: Photobiomodulation therapy (PBMT) with 940nm, 4.1W, 120s, 68.33J/cm2, 0.58W/cm2, three times per week for two weeks (G2)
Number of subjects: 60
Study 31678060 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving sodium naproxen 250mg every 8 hours for 6 days (CG)
Number of subjects: 60
Study 30643959 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional high-intensity interval training (TRAD)
Number of subjects: 17
Study 30643959 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodized high-intensity interval training (PER)
Number of subjects: 17
Study 29068288 — intervention group
Group type: EXPERIMENTAL
Intervention: Early surgical treatment
Number of subjects: 29
Study 29068288 — intervention group
Group type: COMPARATOR
Intervention: Delayed surgical treatment
Number of subjects: 29
Study 25190072 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive statin therapy
Number of subjects: 66
Study 25190072 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline lipid-rich plaque (LRP)
Number of subjects: 66
Study 25190072 — intervention group
Group type: EXPERIMENTAL
Intervention: Large plaque burden with large LRP at baseline
Number of subjects: 66
Study 23241723 — intervention group
Group type: EXPERIMENTAL
Intervention: Adductor Canal Block (ACB)
Number of subjects: 12
Study 23241723 — intervention group
Group type: EXPERIMENTAL
Intervention: Femoral Nerve Block (FNB)
Number of subjects: 12
Study 23241723 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 21597387 — intervention group
Group type: EXPERIMENTAL
Intervention: Linifanib 0.10 mg/kg (low dose)
Number of subjects: 139
Study 21597387 — intervention group
Group type: EXPERIMENTAL
Intervention: Linifanib 0.25 mg/kg (high dose)
Number of subjects: 139
Study 21597387 — intervention group
Group type: EXPERIMENTAL
Intervention: Linifanib (both doses)
Number of subjects: 139
Study 19812066 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-partum single-dose nevirapine
Number of subjects: 330
Study 16901024 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin injection into the musculature adjacent to the wound
Number of subjects: 31
Study 16901024 — intervention group
Group type: COMPARATOR
Intervention: Placebo injection into the musculature adjacent to the wound
Number of subjects: 31
Study 15293866 — intervention group
Group type: EXPERIMENTAL
Intervention: Solifenacin 10 mg (oral)
Number of subjects: 12
Study 15293866 — intervention group
Group type: EXPERIMENTAL
Intervention: Solifenacin 5 mg (intravenous)
Number of subjects: 12
Study 11166784 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg daily for 6 weeks
Number of subjects: 30
Study 11166784 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 30
Study 15321243 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5% lidocaine with epinephrine
Number of subjects: 30
Study 15321243 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% chloroprocaine with sodium bicarbonate
Number of subjects: 30
Study 15321243 — intervention group
Group type: COMPARATOR
Intervention: Control group (elective cesarean section)
Number of subjects: 30
Study 15321243 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine
Number of subjects: 30
Study 15321243 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroprocaine
Number of subjects: 30
Study 8165845 — intervention group
Group type: EXPERIMENTAL
Intervention: Iomeprol 400
Number of subjects: 50
Study 8165845 — intervention group
Group type: COMPARATOR
Intervention: Natrium-meglumine-diatrizoate (Urografin 76)
Number of subjects: 50
Study 2974714 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium
Number of subjects: 3381
Study 2974714 — intervention group
Group type: COMPARATOR
Intervention: Alcuronium
Number of subjects: 3381
Study 2974714 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 3381
Study 31996422 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV envelope vaccination (subtype C, DNA/MVA, phase 1 trial, n=1)
Number of subjects: 18
Study 31996422 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV envelope vaccination (subtype C, DNA/MVA/gp140 protein, phase 1 trial, n=2)
Number of subjects: 18
Study 31996422 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV envelope vaccination (multisubtype, DNA/adenovirus serotype 5 [Ad5], phase 2 trial, n=7)
Number of subjects: 18
Study 31996422 — intervention group
Group type: COMPARATOR
Intervention: Placebo recipients (n=4)
Number of subjects: 18
Study 31996422 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV envelope vaccination (all groups combined)
Number of subjects: 18
Study 31996422 — intervention group
Group type: COMPARATOR
Intervention: Unvaccinated controls (HIV-infected South African individuals)
Number of subjects: 18
Study 30005748 — intervention group
Group type: EXPERIMENTAL
Intervention: Level overlap and color coding
Number of subjects: 0
Study 30005748 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of level overlap and color coding
Number of subjects: 0
Study 30005748 — intervention group
Group type: COMPARATOR
Intervention: Base-case study arm without level overlap or color coding
Number of subjects: 0
Study 27327078 — intervention group
Group type: EXPERIMENTAL
Intervention: Lambda/RBV/DCV
Number of subjects: 440
Study 27327078 — intervention group
Group type: COMPARATOR
Intervention: Alfa/RBV/TVR
Number of subjects: 440
Study 25551592 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% lidocaine spray
Number of subjects: 214
Study 25551592 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 214
Study 22957727 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin treatment
Number of subjects: 16
Study 22957727 — intervention group
Group type: COMPARATOR
Intervention: Validation group (healthy volunteers)
Number of subjects: 16
Study 20496728 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoint catgut implantation
Number of subjects: 65
Study 20496728 — intervention group
Group type: COMPARATOR
Intervention: Medication (2 pills of Fu fuchun capsule, once a day)
Number of subjects: 65
Study 19006920 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 17186726 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug cupping therapy (DCT) with Liuwei Dihuang Pill (LDP)
Number of subjects: 77
Study 17186726 — intervention group
Group type: COMPARATOR
Intervention: Common cupping therapy without drug
Number of subjects: 77
Study 12589012 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based decision support system (CDSS) providing patient-specific information
Number of subjects: 1952
Study 12589012 — intervention group
Group type: COMPARATOR
Intervention: Control (routine practice observed)
Number of subjects: 1952
Study 10907147 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapists' systemic responses measured using a newly developed scale.
Number of subjects: 15
Study 10907147 — intervention group
Group type: EXPERIMENTAL
Intervention: Exploratory analysis of 11 clients excluding overriding factors.
Number of subjects: 15
Study 8853770 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole dual therapy (omeprazole 40 mg o.m. + amoxycillin 500 mg t.d.s.)
Number of subjects: 105
Study 8853770 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole triple therapy (omeprazole 40 mg o.m. + amoxycillin 500 mg t.d.s. + metronidazole 400 mg t.d.s.)
Number of subjects: 105
Study 8853770 — intervention group
Group type: COMPARATOR
Intervention: H. pylori negative patients
Number of subjects: 105
Study 8853770 — intervention group
Group type: COMPARATOR
Intervention: H. pylori positive patients
Number of subjects: 105
Study 8853770 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 105
Study 1289921 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular desipramine (DMI) 75 mg
Number of subjects: 40
Study 1289921 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 6549160 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol (20 mg/kg/day orally for 3 days)
Number of subjects: 0
Study 6549160 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 31883766 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (0.1 mcg/kg/hour) administered during anesthesia and through postoperative day 2
Number of subjects: 0
Study 31883766 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline administered at the same rate for the same duration
Number of subjects: 0
Study 31883766 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 0
Study 30902424 — intervention group
Group type: EXPERIMENTAL
Intervention: HF-POMS tool
Number of subjects: 341
Study 29270001 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg
Number of subjects: 52
Study 29270001 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin 20 mg (Control)
Number of subjects: 52
Study 25668196 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 minute morning and afternoon naps
Number of subjects: 11
Study 25668196 — intervention group
Group type: COMPARATOR
Intervention: No naps
Number of subjects: 11
Study 24667750 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher vegetable consumption (doubling the serving sizes of vegetables)
Number of subjects: 120
Study 24667750 — intervention group
Group type: COMPARATOR
Intervention: Standard healthy diet advice (control group)
Number of subjects: 120
Study 24667750 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher vegetable consumption
Number of subjects: 120
Study 24667750 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (higher vegetable consumption and control)
Number of subjects: 120
Study 21664603 — intervention group
Group type: EXPERIMENTAL
Intervention: Prismatic glasses and optometric correction
Number of subjects: 45
Study 21664603 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 45
Study 19678557 — intervention group
Group type: EXPERIMENTAL
Intervention: Spiritual-hypnosis assisted therapy (SHAT)
Number of subjects: 226
Study 19678557 — intervention group
Group type: COMPARATOR
Intervention: No therapy (control group)
Number of subjects: 226
Study 17446521 — intervention group
Group type: EXPERIMENTAL
Intervention: Original protocol
Number of subjects: 160
Study 17446521 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified protocol
Number of subjects: 160
Study 15213473 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocker sole
Number of subjects: 10
Study 15213473 — intervention group
Group type: COMPARATOR
Intervention: Shoes without rocker soles
Number of subjects: 10
Study 11280344 — intervention group
Group type: EXPERIMENTAL
Intervention: UCS inflation
Number of subjects: 30
Study 11280344 — intervention group
Group type: EXPERIMENTAL
Intervention: UCS deflation
Number of subjects: 30
Study 9260120 — intervention group
Group type: EXPERIMENTAL
Intervention: Vacuum with M-cup
Number of subjects: 637
Study 9260120 — intervention group
Group type: COMPARATOR
Intervention: Forceps
Number of subjects: 637
Study 8297714 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced educational intervention
Number of subjects: 0
Study 8297714 — intervention group
Group type: COMPARATOR
Intervention: Informational educational intervention
Number of subjects: 0
Study 3326567 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodophor-impregnated plastic incise drape
Number of subjects: 1102
Study 3326567 — intervention group
Group type: COMPARATOR
Intervention: Standard skin preparation technique (Control)
Number of subjects: 1102
Study 31560227 — intervention group
Group type: EXPERIMENTAL
Intervention: Bulking laxative and probiotic
Number of subjects: 17
Study 31560227 — intervention group
Group type: COMPARATOR
Intervention: Osmotic laxative
Number of subjects: 17
Study 29486364 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptomatic unilateral gluteal tendinopathy (GT)
Number of subjects: 133
Study 29486364 — intervention group
Group type: COMPARATOR
Intervention: Symptomatic unilateral hip osteoarthritis (HOA)
Number of subjects: 133
Study 27317162 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine (1000 mg/d)
Number of subjects: 47
Study 27317162 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 24824813 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-port laparoscopic inguinal herniorraphy
Number of subjects: 100
Study 24824813 — intervention group
Group type: COMPARATOR
Intervention: Multiport laparoscopic inguinal herniorraphy
Number of subjects: 100
Study 24212170 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard quit smoking counseling program
Number of subjects: 0
Study 24212170 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly intensive quit smoking counseling program
Number of subjects: 0
Study 24212170 — intervention group
Group type: EXPERIMENTAL
Intervention: Postpartum follow-up session
Number of subjects: 0
Study 20299499 — intervention group
Group type: EXPERIMENTAL
Intervention: S‐1 plus cisplatin (2 courses)
Number of subjects: 60
Study 20299499 — intervention group
Group type: EXPERIMENTAL
Intervention: S‐1 plus cisplatin (4 courses)
Number of subjects: 60
Study 20299499 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel plus cisplatin (2 courses)
Number of subjects: 60
Study 20299499 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel plus cisplatin (4 courses)
Number of subjects: 60
Study 19036981 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg of the selective NE‐reuptake inhibitor reboxetine (RBX)
Number of subjects: 62
Study 19036981 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg of hydrocortisone
Number of subjects: 62
Study 19036981 — intervention group
Group type: EXPERIMENTAL
Intervention: Both drugs in combination (RBX and hydrocortisone)
Number of subjects: 62
Study 19036981 — intervention group
Group type: COMPARATOR
Intervention: Single oral dose of placebo
Number of subjects: 62
Study 15696567 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid therapy (prednisone)
Number of subjects: 94
Study 14618666 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnant women
Number of subjects: 36
Study 14618666 — intervention group
Group type: COMPARATOR
Intervention: Non-pregnant women
Number of subjects: 36
Study 10807817 — intervention group
Group type: EXPERIMENTAL
Intervention: salbutamol inhalation via pMDI
Number of subjects: 18
Study 10807817 — intervention group
Group type: EXPERIMENTAL
Intervention: salbutamol inhalation via pMDI + spacer
Number of subjects: 18
Study 10807817 — intervention group
Group type: EXPERIMENTAL
Intervention: salbutamol inhalation via Autohaler
Number of subjects: 18
Study 10807817 — intervention group
Group type: COMPARATOR
Intervention: placebo inhalation
Number of subjects: 18
Study 8614273 — intervention group
Group type: EXPERIMENTAL
Intervention: ENA 713 12 mg/day bid (n=20)
Number of subjects: 50
Study 8614273 — intervention group
Group type: EXPERIMENTAL
Intervention: ENA 713 12 mg/day tid (n=20)
Number of subjects: 50
Study 8614273 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=10)
Number of subjects: 50
Study 8614273 — intervention group
Group type: EXPERIMENTAL
Intervention: ENA 713 (all groups)
Number of subjects: 50
Study 1991653 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin treatment
Number of subjects: 0
Study 1991653 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6140837 — intervention group
Group type: EXPERIMENTAL
Intervention: Live influenza vaccine
Number of subjects: 3
Study 6140837 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated influenza vaccine
Number of subjects: 3
Study 6140837 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 3
Study 31296293 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-Coated Balloon (DCB)
Number of subjects: 192
Study 31296293 — intervention group
Group type: COMPARATOR
Intervention: Drug-Eluting Stent (DES)
Number of subjects: 192
Study 29544728 — intervention group
Group type: EXPERIMENTAL
Intervention: BGF MDI 320/14.4/10 μg
Number of subjects: 84
Study 29544728 — intervention group
Group type: EXPERIMENTAL
Intervention: BGF MDI 80/14.4/10 μg
Number of subjects: 84
Study 29544728 — intervention group
Group type: EXPERIMENTAL
Intervention: BGF MDI 160/14.4/10 μg
Number of subjects: 84
Study 29544728 — intervention group
Group type: COMPARATOR
Intervention: All treatments
Number of subjects: 84
Study 26423265 — intervention group
Group type: EXPERIMENTAL
Intervention: DPOP-Q
Number of subjects: 109
Study 26423265 — intervention group
Group type: COMPARATOR
Intervention: POPstix® POP-Q
Number of subjects: 109
Study 24925070 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) applied on quadriceps and gastrocnemius 10 min before CPET (20 s/site, 850 nm, 100 mW/diode, 14 J/site)
Number of subjects: 18
Study 24925070 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT)
Number of subjects: 18
Study 24925070 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 22504462 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.01 mg/kg/h background infusion plus 0.01 mg/kg bolus (BI)
Number of subjects: 86
Study 22504462 — intervention group
Group type: COMPARATOR
Intervention: 1.5 mg bolus-only morphine (B0)
Number of subjects: 86
Study 20480794 — intervention group
Group type: EXPERIMENTAL
Intervention: Onion extract gel (OE)
Number of subjects: 30
Study 20480794 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% hydrocortisone, silicone and vitamin E lotion (HSE)
Number of subjects: 30
Study 20480794 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 17638395 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil 40 mg once daily
Number of subjects: 2306
Study 17638395 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil 20 mg once daily + Hydrochlorothiazide 12.5 mg once daily
Number of subjects: 2306